Recombinant Antibodies for Autoimmune Diagnostics.

Fonte Standard Gras
Identifiant

Unité de recherche

INNOSUISSE

Numéro de projet

9963.1;5 PFLS-LS

Titre du projet

Recombinant Antibodies for Autoimmune Diagnostics

Titre du projet anglais

Recombinant Antibodies for Autoimmune Diagnostics

Textes relatifs à ce projet

	Allemand	Français	Italien	Anglais
Description succincte	-	-	-
Résumé des résultats (Abstract)	-	-	-

Textes saisis

Catégorie	Texte
Description succincte (Anglais)	Recombinant Antibodies for Autoimmune Diagnostics.
Résumé des résultats (Abstract) (Anglais)	(Feasibility Study, 7-months). This project will pursue the development of advanced assays for human autoimmune diagnosis or disease-state monitoring. In particular, measuring autoimmune response requires having the appropriate human antibodies as necessary for assay development, reference and standardization. As a first step, we will develop recombinant human-mouse chimeric antibodies, specifically anti-ganglioside and anti-myelin-associated glycoprotein (MAG). These will serve functionally as humansimilar material for assay applications, where otherwise human material from natural sources e.g. isolated from diseased individuals, has long proven to be restricting. In the future, we envision a full-spectrum platform, from antigen design or synthesis to the isolation of binding-specific antibodies, followed by recombinant protein expression through full development of further unique diagnostic assays.

Catégorie

Texte

Description succincte
(Anglais)

Recombinant Antibodies for Autoimmune Diagnostics.

Résumé des résultats (Abstract)
(Anglais)

(Feasibility Study, 7-months). This project will pursue the development of advanced assays for human autoimmune diagnosis or disease-state monitoring. In particular, measuring autoimmune response requires having the appropriate human antibodies as necessary for assay development, reference and standardization. As a first step, we will develop recombinant human-mouse chimeric antibodies, specifically anti-ganglioside and anti-myelin-associated glycoprotein (MAG). These will serve functionally as humansimilar material for assay applications, where otherwise human material from natural sources e.g. isolated from diseased individuals, has long proven to be restricting. In the future, we envision a full-spectrum platform, from antigen design or synthesis to the isolation of binding-specific antibodies, followed by recombinant protein expression through full development of further unique diagnostic assays.